Xavier Sansó

Have you signed up for LSI Europe in Portugal yet?  This is a must participate in event if you are a startup or investor in the Medtech, Digital Health, or Diagnostics space!  I have been going every year since 2019 and can tell you it is well worth the time and money to attend.   Definitely utilize the partnering app and set up meetings with investors, strategics, and startups ahead of time! MedTech InnovatorMedTech Innovator Asia PacificBioTools InnovatorY CombinatorTechstarsMedTech StrategistAdvaMedCompany VenturesHealth WildcattersCapital Factory MedTech Startup MedTech World

3

1 comentario

Many factors play a role when fundraising. How fast does ECB's interest rate decisions translate into market actions? #ecb #funding #fundingrounds #venturecapital #privateequity #publicfunding #markets #interestrate #policy #sentiment #investmentstrategies #rateprediction

3

VC in Europe: State of European Tech 24 by Atomico report is out. For sure an interesting read. The ecosystem is still growing quick. In an era where DPI is the new IRR, all eyes are on exits. Report is here: https://lnkd.in/eGdU4Thm #venturecapital #VC #Atomico #privatemarkets

4

Interesting view ! "To identify investments that create sustainable competitive advantage, not just short-term accounting profits, business leaders must relentlessly focus on innovation and keep bolstering intangible capital. Our key message? Don’t be afraid of reporting short-term accounting losses in the pursuit of long-term value."

5

EU still has lot to do, in particular when it comes to the flow of money. This capital markets union just might be the last chance to fix it... #eu #moneyflow #singlemarket #economy #investment #startup #financing #risktaking #innovation #scaleup #growthfunding #growthcapital #investors #investmentstrategies

3

LPs around the world seek some sort of exposure to the #biotech investment category and the market has spoken as to the Forbion platform, with the #Netherlands-based European #lifesciences fund manager raising over EUR 2 billion, exceeding targets for its two newest funds, Forbion Growth Opportunities III and Forbion Ventures VII, by bringing in 1.2 billion euros ($1.3 billion) and 890 million euros ($980 million), respectively. This fundraise significantly overshoots the 1.35 billion euros ($1.5 billion) brought in by Forbion’s previous funds—Forbion Ventures Fund VI and Forbion Growth Opportunities Fund II—in April 2023 - yes, just last year! Key recent, outstanding investment exits include Numab Therapeutics AG subsidiary Yellow Jersey Therapeutics, which was acquired by Johnson & Johnson for $1.25 billion in May, and radiopharma biotech Mariana Oncology, which was bought by Novartis for $1 billion in the same month! We had the opportunity to meet the Forbion leadership team earlier this year in London at the Institutional Limited Partners Association (ILPA) summit and they are indeed quite a remarkable team poised to identifying and backing great teams in the sector. Congratulations to all and looking forward to building the relationship! #alternativeassets #fundraising #fundmanagers #privatemarkets #europe #germany #crossborder #venturecapital #growthcapital #limitedpartners

13

1 comentario

European family offices should allocate more to private equity! By region, family offices in North America allocate 35% of the average portfolio to private equity and 8% for hedge funds; in Latin America, 18% and 2%; in Switzerland, 18% and 3%; in the rest of Europe, 22% and 4%; in the Middle East, 27% and 5%; in North Asia, 18% and 6%; and in Southeast Asia, 19% and 5%. #familyoffice #wealthtransfer #assetallocation #investmentstrategy #investmentmanagement #privateequity #returnoninvestment #portfoliomanagement #risk #return

1

💸 Our business angel cash-out guide is out! 💸 I put together these 4 rules, compiling years of experience advising the best VC investors in managing their portfolio and their exit strategies ( 👋 Romain Afflelou Jean-David BENICHOU Jeremie Attali Marc Menasé Patrice Giami Fanny MIARA) For early-stage investors, finding the right monetization path is a significant challenge. The best, and most complex, option is selling shares on the secondary market. I put together this guide to help early stage venture investors maximize their returns, structured around four major rules RULE 👍 : Prepare this transaction strategy ahead of time RULE 🤘 : Find the right timing to do so RULE 👌 : Price their shares on the secondary market RULE 👊 : Efficiently manage your secondary process You can access the full version of the guide on https://lnkd.in/eqY2XQ_M If you want advice on how to maximize your portfolio I am more than happy to seat with you and discuss your strategy - just book a timeslot in my agenda https://lnkd.in/eFCPXU_g #venturecapital #businessangel #ROI #secondary #portfoliomanagement

43

2 comentarios

“A total of 88 companies have delisted or transferred their primary listing from London’s main market this year with only 18 taking their place”. Friends don’t let friends list in Europe. European public markets desperately need an overhaul. They’re the minor leagues. “This marks the biggest net outflow of companies from the main market since 2009, while the number of new listings is also on course to be the lowest in 15 years”. 😬 https://lnkd.in/eHsxYN8z

331

41 comentarios

The last report released by Invest Europe on the state of the European VC industry contains some great data on the role that VC companies are playing in helping the European economy grow (link in the comments). But I do have to (again) take serious issue with the performance data they use and the claim that European VC has outperformed its US peers over the last decade. Invest Europe uses the Cambridge Associates data when analysing the performance of European venture capital. However, the analysis is only as good as the underlying data and, unfortunately, Cambridge's data on European VC fund performance is extremely limited. According to Pitchbook, there were 2,733 VC funds raised in Europe (including the UK) from 2010 to 2019. However, just 88 of these are included in Cambridge's European benchmarks. That equates to just 3.2% of all the funds raised during the period. In some vintage years, there are just three funds in the Cambridge analysis! In a power law asset class such as venture, a 3.2% sample size will produce conclusions that are, at best, meaningless and, at worst, misleading. The most you can honestly say about this data is that the tiny sample of European funds in the Cambridge data has outperformed the slightly larger, but still small (13.3% of all funds raised) sample of US funds. You cannot extrapolate this data to say European VC funds outperform US ones. We have been investing in European venture funds for over 25 years and there are some outstanding VC firms in the region. If investors want to commit to European VCs, they should do it because they believe that specific firm to be one of the best VC managers globally. Allocating to venture capital based on average performance from a highly limited data set is not a winning strategy.

70

7 comentarios

Very interesting to get the chance to talk to Torsten Osthus, of OSTHUS GROUP and cofounder of ZONTAL about #labdigitalization #scientificdata #FAIRdata #datastandards and their potential for #AI #ArtificialIntelligence application in the #lifesciences

16

The European VC fundraising scene is showing a clear trend: experience matters. Let's unpack some data on this from The State of European Fundraising Report. 1/ Why track record matters. In a cautious market, LPs (investors) are prioritizing established funds with a proven history of success. Experienced firms captured 54.5% of the capital raised in 2023. 2/ New opportunities for LPs. This market shift presents a golden opportunity for LPs to build relationships with top-tier VC firms. Firms they might not have accessed before. 3/ Focus on creating value. Investors are seeking firms that prioritize building real value, not just hype. This is a great long-term trend for the industry. If you are en emerging fund manager, the time to build a strong reputation and track record is now. Focus on building a compelling value proposition and demonstrating a clear path to success to attract investors. Learn how to navigate the effects of the #TechReset. Get insights from The State of European Fundraising Report. ➡️ buff.ly/4aYglgi Delivered to you by EUVC | Isomer Capital | Floww. #EUVC #fundraising #venturecapital #industryreport

12

1 comentario

When you pitch a VC investor... They will look you up on LinkedIn. First impressions matter. We all know it. We focus on: - Profile photos - Taglines - About sections But without a strategy, Your profile won't stand out. This is where the "2025 LinkedIn Profile Optimization Guide" by Justin Welsh comes in: 1. Profile Design ↳ Use the banner image to brand your business or products. ↳ Ensure your profile photo is high-quality and matches your desired tone. 2. Tagline ↳ Make it clear who you help and what you achieve. ↳ Highlight the outcomes of your work. 3. Featured Section ↳ Direct viewers to websites, newsletters, or product pages. ↳ Control your narrative by showcasing external resources. 4. About Section ↳ Share a compelling story with key achievements. ↳ Highlight tangible results that show your impact. LinkedIn's Value: The platform is a powerful tool for creators and startup founders. It can boost your follower count and business impact. Treat your profile as a strategic tool to convert viewers into followers, customers, or collaborators. For advanced learning, check out Welsh's course, "The LinkedIn Operating System." It details strategies to grow your influence and income on LinkedIn. Join thousands of founders and VCs who receive these insights in my biweekly newsletter at https://lnkd.in/e8tUxsTk And follow 👉 Igor Curic, CFA, MBA for more content like this!

20

1 comentario

European Family Office VC Investing As we have been repeating for some time, the real interest by European institutional investors to allocate their capital into VC funds is negligible.📉 We see that institutional LPs in Europe versus their US counterparts are not even close to investing in VC & PE strategies. Recently, the largest US LP CalPERS increased its allocation to the VC funds and so did some University endowments. The only bright stars in Europe are the European Investment Fund (EIF), KfW Capital , British Business Bank, and Bpifrance.🌟 The Swiss SFO allocation chart is just another proof of the current risk-averse mindset of European investors and supports the view among GPs and VC operators in Europe.🚩 When will this change, no one knows🤷‍♂️ Thanks to Ertan Can for sharing ✅ Looking to raise capital for your #VCfund and increase the international pool of your LPs?   🤝 Need warm #LP introductions?   📝 Selling #secondaries to increase liquidity?   🧐 Looking for co-investments (Series A/Series B)?   ▶ G+QUANT's link for inquiries and fund decks: https://lnkd.in/gjC_EuTE #VentureCapital #VentureFunding #VentureDebt #Fundraising #Innovation #Technology #Entrepreneurship #Investing #Network #Investors #LPs #GPs #EmergingManagers #FamilyOffice #Markets #Economy #Business #Founders #Startups #StartupFunding #ai #artificialintelligence #unicorn #secondaries #secondarydeals

11

13 comentarios

Why is European private equity attracting record capital? The past few years have been challenging for private equity dealmakers. However, experienced managers with proven track records continue to attract significant capital. I am pleased to see that European firms have been particularly successful. Data shows they've raised nearly €118 billion last year — almost matching the record set in 2021. In my view, these numbers reflect the ongoing confidence in private equity, despite economic uncertainties. Our research team has compiled a detailed report on how European private equity performed over the last year. I invite you to explore the report available at the link below. #EuropeanPE #Dealmaking #PrivateEquity #VentureCapital #PrivateMarkets #Consulting #investing #Wealth #AssetManager #Fintech #Investment

36

1 comentario

At WAD Capital, we focus on selecting great leaders to drive the next phase of growth for European SMEs. Our four-stage selection process is designed to identify entrepreneurs with the skills and commitment needed to build on the strengths of these businesses. What makes our approach unique is that we select CEOs who are already exceptional operators with proven track records. During our intensive search phase, we transform these experienced executives into sophisticated investment managers. Our CEOs learn to analyze markets, sectors, and verticals with the rigor of traditional private equity firms while maintaining their operator's mindset. This dual expertise - combining deep operational experience with investment acumen - enables our CEOs to identify the most promising opportunities in their target markets. Starting from a pool of 500 candidates, we select 10 CEOs who not only align with our approach to sustainable growth, innovation, and responsible impact, but who also demonstrate the ability to bridge the operator-investor divide. The result? Leaders who understand both the operational complexities of running a business and the strategic considerations of building long-term value. Are you an experienced operator ready to expand your skillset and shape the future of European business? Let's connect. #WADCapital #Leadership #BusinessGrowth #ValueCreation #ExecutiveSearch #ThenextstepasCEO #succession #SmallCap

20

In vitro diagnostics for early cancer detection has often been a graveyard for investors. Investors are attracted by the undoubtedly huge market potential. If a company can develop a diagnostic test that is implemented as a population level screening tool, this is the definition of a venture scale opportunity. However, multiple factors are at play that make the journey far from easy. You need a highly sensitive and specific test that allows you to minimise false positives and false negatives. This is because the burden of over diagnosis and over treatment against a change in overall mortality rates is a finely tuned balancing act. You'd also want to ensure that the screening tool was applicable to multi-cancer detection, going further than just a rule-out test, by predicting the origin site of a particular cancer. As a pre-seed/seed investor what we are often looking for is deep scientific domain expertise, coupled with credibility to achieve a proof-of-concept data point and/or prototypes. Our latest investment at Empirical Ventures into Xgenera and the dynamic duo Dr Andy Shapanis and Prof Paul Skipp might just be the right starting point for approaching this opportunity. Their multi cancer early detection test (MCED) called miONCO was developed from analysing relative expression profiles of microRNAs in 20,000 patient samples. Xgenera’s two step test would detect cancer using a computational algorithm to identify microRNA profiles extracted from patient blood samples, and can predict the site of origin of the cancer. As a screening test this could improve patient lives significantly. I believe Xgenera has the right technology, at the right time, based around recent advances in computational speed and power, post-COVID knowledge moats related to qPCR scale-up and novel biomarkers such as microRNAs to capitalise on this potential. Read more about it below. I can't wait to join the board to support the team as they navigate the 0 to 1 phase of this journey. CAPITAL AT RISK. FOR PROFESSIONAL INVESTORS ONLY. https://lnkd.in/dNpuSERg

42

1 comentario

I'm delighted to announce the launch of the TempoCap Liquidity Indices, which, on a quarterly basis, track the largest European VC-backed exits since January 2020. We are tracking three main types of exits: all cash, cash and shares, and public listings.   We struggled to find this information in a single place or in a comprehensive format, so we decided to compile it ourselves from a range of data sources. Of course, we may have missed some exits, so please don't hesitate to get in touch if we have.   Here are a few notable trends from the data: 🔴 On all cash exits: A limited number of these were above $1 billion in Europe over the last nearly five years - we counted only five. Out of the top 15 cash exits, six were companies from the U.K., four from Germany, three from France, and two from Scandinavia - including the largest, Tink. 14 out of the top 15 exits were to strategics (with only one PE buyer), and 60% of buyers were U.S. companies. The average time to exit from the founding date was ten years. 🔴 On exits for cash and shares: There have been a limited number of these above $1 billion in Europe over the last circa five years, too —we counted only four. The U.K. had five companies out of the top 15, and interestingly, two each came from Poland and Germany, while the largest, Wolt, is Finnish. Again, 60% of buyers were from the U.S. The average time to exit from the founding date is nine years. 🔴 On public listings: Here, all 15 listings were above $1 billion—but some didn't stay above that level post-IPO, and three are no more! Out of the top 15, seven (or nearly half) came from the U.K., three came from Germany, and the largest, UI Path, came from Romania. The average time to IPO from the founding date was 11 years. We have researched various sources to ensure that we have the most accurate information possible, but if you've spotted something that needs to be corrected or a company that needs to be added, please let us know at [email protected].

85

7 comentarios